alipogene tiparvovec

AXP000248.1 · Viral vector gene therapy

Platform
AAV1 vector
Targets
LPL
Originator
Amsterdam Molecular Therapeutics
Sponsor
uniQure

Names

NameTypeSource
alipogene tiparvovecpreferred namecurator
Glyberabrandcurator
AMT-011former codecurator

Virus

Role
In vivo gene transfer
Family
Parvoviridae
Virus
adeno-associated virus 1
Strain
AAV1
Replication
non replicating
Transgenes
LPL (S447X variant)
Route
intramuscular
Source
evidence

Approvals

AgencyRegionDateStatusBrandIndicationSource
EMAEU2012-10-25withdrawnGlyberaFamilial lipoprotein lipase deficiency with severe or multiple pancreatitis attacks despite dietary fat restriction; authorisation expired 2017-10-28source

Clinical trials (5)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT02904772Alipogene Tiparvovec for the Treatment of LPLD PatientsWithdrawnPhase 22016-102020-060LPL Deficiency
NCT03293810Glybera Registry, Lipoprotein Lipase Deficient (LPLD) PatientsCompleted2014-06-272023-0616Familial Hyperchylomicronemia; Familial Hyperlipoproteinemia Type 1; Lipoprotein Lipase Deficiency
NCT01447901Duration of Effect of Alipogene Tiparvovec Treatment, Which Was Administered in Other StudiesTerminated2011-092012-0919Hyperlipoproteinemia Type I
NCT00891306Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient SubjectsCompletedPhase 2/32009-022010-085Familial Lipoprotein Lipase Deficiency
NCT01109498Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X]UnknownPhase 2/32007-082013-0614Familial Lipoprotein Lipase Deficiency

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 29641318Gene Therapy in Lipoprotein Lipase Deficiency: Case Report on the First Patient Treated with Alipogene Tiparvovec Under Daily Practice Conditions.Human gene therapy2018name in title: alipogene tiparvovec
PMID 24299335Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy.Human gene therapy2014name in title: alipogene tiparvovec
PMID 22717743Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial.Gene therapy2013cited by trial NCT01109498
PMID 22438229Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients.The Journal of clinical endocrinology and metabolism2012cited by trial NCT00891306

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 40928580Making Advanced Therapies Affordable and Accessible: Two Strategic Approaches.Developing world bioethics2026name in abstract: Glybera
PMID 37597209Preclinical Development and Characterization of Novel Adeno-Associated Viral Vectors for the Treatment of Lipoprotein Lipase Deficiency.Human gene therapy2023name in abstract: Glybera
PMID 38462459Viral Vectors in Gene Replacement Therapy.Biochemistry. Biokhimiia2023name in abstract: Glybera
PMID 36204465Genetic engineering of baculovirus-insect cell system to improve protein production.Frontiers in bioengineering and biotechnology2022name in abstract: Glybera
PMID 33594520Evolving AAV-delivered therapeutics towards ultimate cures.Journal of molecular medicine (Berlin, Germany)2021name in abstract: Glybera
PMID 34790341An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models.Journal of market access & health policy2021name in abstract: Glybera
PMID 31617173Engineering HSV-1 Vectors for Gene Therapy.Methods in molecular biology (Clifton, N.J.)2020name in abstract: alipogene tiparvovec
PMID 31738617Recent developments in pharmacotherapy for hypertriglyceridemia: what's the current state of the art?Expert opinion on pharmacotherapy2020name in abstract: alipogene tiparvovec
PMID 31836454Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery.Pharmacology & therapeutics2020name in abstract: Glybera
PMID 31982038Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans.Molecular therapy : the journal of the American Society of Gene Therapy2020name in abstract: Glybera
PMID 30333169High-Resolution Structural Characterization of a New Adeno-associated Virus Serotype 5 Antibody Epitope toward Engineering Antibody-Resistant Recombinant Gene Delivery Vectors.Journal of virology2019name in abstract: Glybera
PMID 30702996Lipid-Lowering Agents.Circulation research2019name in abstract: alipogene tiparvovec
PMID 30968714The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost.Human gene therapy. Clinical development2019name in abstract: alipogene tiparvovec
PMID 31261383Next-generation AAV vectors-do not judge a virus (only) by its cover.Human molecular genetics2019name in abstract: Glybera
PMID 31283441Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here?Annual review of virology2019name in title: Glybera
PMID 29351106The role of patient registries for rare genetic lipid disorders.Current opinion in lipidology2018name in abstract: alipogene tiparvovec
PMID 29491255A Novel Approach to the Treatment of Plasma Protein Deficiency: Ex Vivo-Manipulated Adipocytes for Sustained Secretion of Therapeutic Proteins.Chemical & pharmaceutical bulletin2018name in abstract: Glybera
PMID 29723270Creating an arsenal of Adeno-associated virus (AAV) gene delivery stealth vehicles.PLoS pathogens2018name in abstract: Glybera
PMID 29842811Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome.Expert review of clinical pharmacology2018name in abstract: alipogene tiparvovec
PMID 30298129Recent Progress in European Advanced Therapy Medicinal Products and Beyond.Frontiers in bioengineering and biotechnology2018name in abstract: Glybera
PMID 30403015Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy.Korean circulation journal2018name in abstract: alipogene tiparvovec
PMID 31282760The rapidly evolving state of gene therapy.FASEB journal : official publication of the Federation of American Societies for Experimental Biology2018name in abstract: Glybera
PMID 27548881The potential of toxin-based drug delivery systems for enhanced nucleic acid therapeutic delivery.Expert opinion on drug delivery2017name in abstract: alipogene tiparvovec
PMID 27762892Evaluating the Past, Present, and Future of Regenerative Medicine: A Global View.Tissue engineering. Part B, Reviews2017name in abstract: Glybera
PMID 27984852Biochemical Analysis of the Lipoprotein Lipase Truncation Variant, LPLS447X, Reveals Increased Lipoprotein Uptake.Biochemistry2017name in abstract: alipogene tiparvovec
PMID 28284702The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency.Atherosclerosis2017name in abstract: alipogene tiparvovec
PMID 28351174Manufacturing Clinical Grade Recombinant Adeno-Associated Virus Using Invertebrate Cell Lines.Human gene therapy2017name in abstract: Glybera
PMID 28560211Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe.Frontiers in medicine2017name in abstract: Glybera
PMID 28591128After Glybera's withdrawal, what's next for gene therapy?Nature biotechnology2017name in title: Glybera
PMID 28749065Concise Review: The High Cost of High Tech Medicine: Planning Ahead for Market Access.Stem cells translational medicine2017name in abstract: Glybera
PMID 29101575Current and Future Treatments for Lysosomal Storage Disorders.Current treatment options in neurology2017name in abstract: Glybera
PMID 29259533Regulatory Considerations for Gene Therapy Products in the US, EU, and Japan.The Yale journal of biology and medicine2017name in abstract: alipogene tiparvovec
PMID 26519140Progress and challenges in viral vector manufacturing.Human molecular genetics2016name in abstract: Glybera
PMID 27148842The Future of Hemophilia Treatment: Longer-Acting Factor Concentrates versus Gene Therapy.Seminars in thrombosis and hemostasis2016name in abstract: Glybera
PMID 27412455Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis.Human gene therapy2016name in title: alipogene tiparvovec
PMID 27448786Human gene therapy: novel approaches to improve the current gene delivery systems.Discovery medicine2016name in abstract: Glybera
PMID 25559420Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency.Drugs2015name in title: alipogene tiparvovec
PMID 25633169Glybera's second act: the curtain rises on the high cost of therapy.Molecular therapy : the journal of the American Society of Gene Therapy2015name in title: Glybera
PMID 25748892$1-million price tag set for Glybera gene therapy.Nature biotechnology2015name in title: Glybera
PMID 25800821The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors.Biotechnology journal2015name in abstract: Glybera
PMID 26052534Re-examination of regulatory opinions in Europe: possible contribution for the approval of the first gene therapy product Glybera.Molecular therapy. Methods & clinical development2015name in title: Glybera
PMID 26236188Gene therapy and peripheral nerve repair: a perspective.Frontiers in molecular neuroscience2015name in abstract: Glybera
PMID 26780002Novel therapeutics in hypertriglyceridemia.Current opinion in lipidology2015name in abstract: alipogene tiparvovec
PMID 26780008Gene-based therapies in lipidology: current status and future challenges.Current opinion in lipidology2015name in abstract: Glybera
PMID 24308784Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®).Expert review of clinical pharmacology2014name in title: alipogene tiparvovec
PMID 24624131Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside.Frontiers in immunology2014name in title: Glybera
PMID 24649836Clinical development of gene therapy needs a tailored approach: a regulatory perspective from the European Union.Human gene therapy. Clinical development2014name in abstract: alipogene tiparvovec
PMID 24671677Engineering HSV-1 vectors for gene therapy.Methods in molecular biology (Clifton, N.J.)2014name in abstract: alipogene tiparvovec
PMID 24845847Gene therapy: a promising approach to treating spinal muscular atrophy.Human gene therapy2014name in abstract: Glybera
PMID 25083925Recent advances in pharmacotherapy for hypertriglyceridemia.Progress in lipid research2014name in abstract: alipogene tiparvovec
PMID 25091489State-of-the-art human gene therapy: part I. Gene delivery technologies.Discovery medicine2014name in abstract: Glybera
PMID 25393537Intramuscular injection of AAV8 in mice and macaques is associated with substantial hepatic targeting and transgene expression.PloS one2014name in abstract: Glybera
PMID 25459120Gene therapy of the central nervous system: general considerations on viral vectors for gene transfer into the brain.Revue neurologique2014name in abstract: Glybera
PMID 25468918Dyslipidaemia: what's around the corner?Clinical medicine (London, England)2014name in abstract: alipogene tiparvovec
PMID 23126631Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency.Expert opinion on biological therapy2013name in title: alipogene tiparvovec
PMID 23527320Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency.Drugs of today (Barcelona, Spain : 1998)2013name in title: alipogene tiparvovec
PMID 23566848Gene therapy on demand: site specific regulation of gene therapy.Gene2013name in abstract: Glybera
PMID 23618815History of gene therapy.Gene2013name in abstract: Glybera
PMID 23808604Lessons learned from the clinical development and market authorization of Glybera.Human gene therapy. Clinical development2013name in title: Glybera
PMID 23954897Regulatory evaluation of Glybera in Europe - two committees, one mission.Nature reviews. Drug discovery2013name in title: Glybera
PMID 22340447New lipid-lowering drugs: an update.International journal of clinical practice2012name in abstract: alipogene tiparvovec
PMID 22679644Glybera and the future of gene therapy in the European Union.Nature reviews. Drug discovery2012name in title: Glybera
PMID 22691709Gene therapy for lipoprotein lipase deficiency.Current opinion in lipidology2012name in abstract: alipogene tiparvovec
PMID 23023051Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union.Molecular therapy : the journal of the American Society of Gene Therapy2012name in title: Glybera
PMID 20427244Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency.Atherosclerosis. Supplements2010name in title: alipogene tiparvovec
PMID 19455266Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2009name in abstract: alipogene tiparvovec
PMID 20072945Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency.Current opinion in molecular therapeutics2009name in title: alipogene tiparvovec

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R01EB034573Engineering the biology of AAV secretion and productionDUKE UNIVERSITYASOKAN, ARAVIND2023–2026name in abstract: Glybera

Notes

First gene therapy authorised in the EU (Glybera, 2012), for familial lipoprotein lipase deficiency. The authorisation expired on 28 October 2017 after uniQure chose not to apply for renewal, citing lack of demand; recorded as withdrawn, the nearest status the spec offers.

How to cite

alipogene tiparvovec (AXP000248.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000248.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.